Results 101 to 110 of about 28,869 (265)

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

Haemophilia, Volume 32, Issue 3, Page 584-592, May/June 2026.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg   +5 more
wiley   +1 more source

2016 Pipeline Report HIV and TB [PDF]

, 2016
HIV and TB: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in ...
Erica Lessem, Lindsay McKenna, Mark Harrington, Mike Frick, Polly Clayden, Richard Jefferys, Simon Collins, Tim Horn   +7 more
core  

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe [PDF]

, 2018
Background: HBsAg immune-escape mutations can favor HBV-transmission also in vaccinated individuals, promote immunosuppression-driven HBV-reactivation, and increase fitness of drug-resistant strains.
Alvarez, M.R. (Marta), Ben Ari, Z. (Ziv), Boland, G.J. (Greet), Boucher, C.A.B. (Charles), Bruzzone, B. (Bianca), Colagrossi, L. (Luna), Coppola, N. (Nicola), Di Carlo, D., Dyda, T. (Tomasz), Garcia, F. (Federico), Hermans, L.E. (Lucas Etienne), Kaiser, R. (Rolf), Krarup, H.B. (H.), Köse, S. (Sukran), Lazarevic, I. (Ivana), Lepej, S.Z. (Snjezana), Lunar, M.M. (Maja M.), Maylin, S. (Sarah), Micheli, V. (Valeria), Mor, O. (Orna), Paraschiv, C. (Corina), Paraskevis, D. (Dimitrios), Pas, S.D. (Suzan), Perno, C.F. (Carlo), Poljak, M. (Mario), Puchhammer-Stöckl, E. (Elisabeth), Salpini, R. (Romina), Seguin-Devaux, C., Simon, F. (François), Stanojevic, M. (Maja), Stene-Johansen, K. (Kathrine), Svicher, V. (Valentina), Tihic, N. (Nijaz), Trimoulet, P. (Pascale), Verheyen, J. (Jens), Vince, A. (Adriana), Weis, N. (Nina), Wensing, A. (Amj), Yalcinkaya, T. (Tülay)   +38 more
core   +2 more sources

Tenofovir alafenamide revisited.

Le infezioni in medicina, 2021
Two Tenofovir pro-drugs are available for the treatment of HIV and HBV infection. Tenofovir Alafenamide (TAF) was clinically developed as a safer alternative to the older Tenofovir Disoproxil Fumarate (TDF) as the latter was consistently found to be associated to proximal renal tubule dysfunction and decrease in bone mineral density (BMD).
openaire   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, Volume 27, Issue 5, Page 727-739, May 2026.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Distinct Lipidomic Profiles between People Living with HIV Treated with E/C/F/TAF or B/F/TAF: An Open-Label Prospective Cohort Study

Infectious Diseases and Therapy
Introduction Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) has been increasingly replaced by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in the treatment of human immunodeficiency virus (HIV) owing to its more ...
Zhikai Wan, Junwei Su, Xueling Zhu, Xiang Liu, Yongzheng Guo, Dairong Xiang, Xiaotang Zhou, Xiaorong Peng, Ran Tao, Qing Cao, Guanjing Lang, Ying Huang, Biao Zhu   +12 more
doaj   +1 more source

Hepatitis B Management in the Middle East: A Narrative Review of Current Antiviral Treatments

Gastrointestinal Disorders
Introduction: Chronic hepatitis B (CHB) is a significant public health issue worldwide, especially in the Middle East region. Around 8% to 20% of patients with CHB develop cirrhosis, which may progress to hepatocellular carcinoma.
Hannah Beck, Nishaanth Dalavaye, Kalaikshiga Kengadaran, Mosammath Monira Khatun, Ria Hitesh Patel, Taif Al-Rubaye, Laith Alrubaiy   +6 more
doaj   +1 more source

Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service

AIDS Research and Therapy, 2019
Background Tenofovir disoproxil fumarate (TDF) is widely used in the management of HIV-infection, but has been associated with renal impairment in a small proportion of patients.
Dane Turner, Douglas Drak, Catherine C. O’Connor, David J. Templeton, David M. Gracey   +4 more
doaj   +1 more source

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, Volume 27, Issue 5, Page 803-808, May 2026.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source

High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence

Journal of Medical Virology
BRAAVE (NCT03631732), a Phase 3b, multicenter, open‐label US study, demonstrated the efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among Black individuals with suppressed HIV through 48 weeks. Here, 72‐week resistance,
Kristen N. Andreatta, M. D’Antoni, Silvia Chang, Aiyappa Parvangada, Ross Martin, C. Blair, D. Hagins, Princy N. Kumar, J. Hindman, Hal Martin, C. Callebaut   +10 more
semanticscholar   +1 more source